Psoriasis is an immune-mediated disease where the IL-23/Th17 axis as well as TNF comprise main targets of biological therapy. Immune profiling has so far not been embraced as a clinical tool. We aimed to investigate relationships between individual serum cytokine levels in 40 psoriasis patients before and after receiving biological therapy and Psoriasis Area and Severity Index (PASI) and Dermatological Life Quality Index (DLQI). Serum concentration of 25 cytokines was determined by Luminex technology. Mean PASI and DLQI decreased by 71% and 65%, respectively. Increase of IL-2 positively correlated with improvement of PASI and DLQI. Moreover, increase of IL-5, IL-10, IL-12, IL-22 and GM-CSF correlated with treatment effect. Notably, logistic regression revealed four times higher risk of having severe psoriasis when IL-17A increased by 1 pg/mL (OR: 4.06, P < 0.05). Selected serum cytokines might constitute useful biomarkers for monitoring disease activity and optimizing therapeutic strategies in psoriasis patients.
| INTRODUCTION
Cytokine targeted therapy is a rapidly evolving field of treatment for many immune-mediated diseases. However, mapping of an individual's cytokine profile before initiating biological treatment is not in routine clinical use. The decisions of which drugs to choose are often based on economical or practical reasons and preferences.
Psoriasis is a chronic inflammatory immune-mediated skin disease associated with increased risk of arthritis, cardiovascular disease, obesity and diabetes. 1, 2 Living with severe skin disease and comorbidities can impact quality of life. Physical trauma, certain infections, stress or medications can trigger and subsequently maintain an eruption of psoriasis in genetically predisposed individuals. 3 Skin damage may induce keratinocyte-derived antimicrobial peptides, which have chemoattractant and immunomodulatory and are upregulated in early psoriasis plaques. 6, 7 Furthermore, myeloid DCs (mDCs) are markedly increased in psoriatic skin and can release nitric oxide, a vasodilating agent affecting skin vasculature. More importantly, when mDCs are stimulated by IFN-α, TNF-α, IL-1 β and IL-6, they secrete IL-12 and IL-23. These cytokines are instrumental in the activation and differentiation of naïve T cells into T helper cells (Th)1 and Th17 cells, respectively, in the draining lymphnode. 8, 9 Th1 cells in turn secrete TNF, IFN-γ and IL-2, while IL-17A, IL-17F and IL-22 are produced by Th17 and Th22 cells. 10 In addition, chemotactic cytokines, (ie, chemokines, eg, CXCL8, CXCL9, CXCL10, CXCL11 and CCL20 11 ) and S100 proteins from keratinocytes also take part in the pathogenesis, together with complementary TNF and IFN-α from natural killer T (NKT) cells. 12, 13 The inflammatory cytokines IL-22 (from Th cells) and IL-20 (from keratinocytes, DC and macrophages) are increased in psoriatic skin lesions and induce keratinocyte hyper-proliferation. 14 A vicious cycle can ensue where inflammatory cytokines from activated keratinocytes act on innate and adaptive immune cells and sustain the inflammatory cascade. 3 Neutrophils gathered in epidermal microabscesses contain IL-17A and are a characteristic feature of psoriasis. It has been shown that they are numerically dominant in the skin compared to IL-17A-containing T cells in active psoriasis. 15 From the complex interplay between immune cells and cytokines in the pathogenesis of psoriasis, TNF-α, IL-12/23 and IL-17 stand out as key cytokines and serve as targets for biological drugs. 9 The aim of this study was to investigate putative relationships between serum cytokines in psoriasis patients before and after initiating biological (anti-cytokine) therapy, with focus on intra-individual changes, and relate this to disease severity and quality of life. In this way, we wanted to explore whether cytokine measurements could be of value in a clinical setting for evaluation of disease activity and treatment effects, thereby enabling individually tailored therapy.
| MATERIALS AND METHODS
Serum samples were collected at the Department of Dermatology, Haukeland University Hospital from April 2015 until August 2017. Inclusion criteria were severe psoriasis, age above 18 years and need of biological treatment. A total of 40 psoriasis vulgaris patients were included, with 10 consecutive patients each prescribed infliximab (anti-TNF-α antibody), ustekinumab (anti-IL12/23 antibody), secukinumab (anti-IL17A antibody) or etanercept (TNFreceptor blocker). The patients' characteristics are displayed in Table 1 and previous and co-medication in Table S1 . All patients were naïve to the biological drug they were prescribed at inclusion, and blood was collected prior to initiation of this treatment but after the recommended washout period of any previous biological drug. At the first time point, patients had active psoriasis with extensive skin inflammation. The follow-up sample was taken after approximately 16 weeks, preferably before a scheduled infusion or injection. Blood was drawn in the morning in 5 mL serum tubes with no additive (BD Vacutainer 367614). The tubes were carefully inverted six times and rested in room temperature (RT) for 60 minutes for coagulation before centrifugation at 2000× g for 10 minutes (RT). Serum was aliquoted and stored at −70°C until analysis. Psoriasis Area and Severity Index and body mass index (BMI) were measured by the treating dermatologist, and Dermatological Life Quality Index questionnaire was completed on the same day. Patients gave written informed consent (Regional ethical committee approvals 2014/1373 and 2014/1489).
| Cytokine analysis
Cytokines were measured using a ProcartaPlex 
| Statistics
The statistical package for social science (SPSS) Statistics 24 (IBM, Armonk, NY, USA) was used for data analysis. Wilcoxon signed rank test for paired samples was applied to investigate the differences in parameters between inclusion and follow-up. The strength of correlations, revealed by Spearman's rank-order test, were interpreted according to the recommendation from British Journal of Medicine (https://www.bmj.com/about-bmj/resources-readers/publica tions/statistics-square-one/11-correlation-and-regression), with ρ: 0.00-0.19 regarded as very weak, 0.20-0.39 as weak, 0.40-0.59 as moderate, 0.60-0.79 as strong and 0.80-1.00 as very strong correlation. Linear regression was used to explore whether the different cytokines could predict disease severity. To evaluate the effect of cytokines on 50%, 75% or 90% improvement of PASI (PASI50, PASI75, PASI90), logistic regression was applied. Δ value was calculated by substracting cytokine value at follow-up from value at inclusion. Fold change (FC) was calculated by dividing cytokine value at follow-up by value at inclusion. Analyses were done on the whole patient group, adjusted for age, gender, BMI and one outlier for IFN-γ, IL-1β, IL-18 and IL-21. A P-value ≤0.05 was considered statistically significant. As the analyses were exploratory, no correction for multiple comparisons was made. Figures were made in GraphPad Prism 7.
| RESULTS

| Disease severity and treatment effect
The clinical measures PASI and DLQI both decreased during treatment, with 71% and 65% reduction of mean values, respectively, for the whole group. 35 of 40 patients achieved at least PASI50, 20 patients PASI75 and eight patients reached PASI90 response. Patients receiving infliximab or secukinumab had the largest improvement of clinical parameters (PASI 80.2% and 75.3%, DLQI 81.8% and 73.1%, respectively), while the amelioration for patients on etanercept and ustekinumab was slightly inferior (PASI 62.5% and 66.2%, DLQI 67.4% and 37.2%, respectively) (Table 1, Figure 1 ). Treatment effect of etanercept can increase for up to 24 weeks 16 implying that further improvement in this group could be anticipated.
| Cytokine levels at inclusion and follow-up
Further analyses encompassed serum levels of cytokines before and approximately 16 weeks after introduction of biological therapy, their interrelationship and fold changes (FC). Serum cytokine levels at inclusion and follow-up are displayed in Figure 2 . Some cytokines were detected in most serum samples (ie, IL-22, IL-1RA, IL-7, IL-18 and IFN-γ), while others (ie, granulocyte-macrophage colonystimulating factor (GM-CSF), IL-2 and IL-21) were detected in around ¼ of the samples, and the remaining cytokines were detected in less than 25 of the 80 samples. Three cytokines (ie, IL-23, IL-31 and lymphotoxin) were not detected by this assay. Wilcoxon signed rank test revealed significant increases in cytokine level at follow-up for IL-5 (P < 0.05) and IL-15 (P < 0.05), but only a few patients contributed to this increase. Concomitant use of methotrexate did not seem to have a major impact on cytokine levels ( Figure S1 ). Subgroup analysis of cytokines was not robust due to limited number of patients included.
The mean TNF, IL-12 and IL-17A at inclusion and followup for the four treatment groups are displayed in Figure S2 but should be interpreted with caution due to low number of values for each condition. Body mass index was correlated to inclusion values of TNF-α (ρ: 0.38, P < 0.05), IL-22 (ρ: 0.38, P < 0.05) and IL-1 RA(ρ: 0.44, P < 0.001).
| Relationship between different cytokines
In order to investigate putative relationships between proand anti-inflammatory cytokines, Spearman correlation was (Table S4) .
To shed light on the pathogenic mechanisms in psoriasis, linear regression was used to investigate whether inclusion levels of cytokines from Th1 cells (TNF, IFN-γ and IL-2) and Th17 (IL-17) could be predicted by levels of cytokines that are considered to be upstream in the cytokine cascades ( Table S5) 
| DISCUSSION
Finding the most effective treatment for patients with immune-mediated diseases can be challenging and often entails multiple treatment attempts resulting in prolonged suffering and unnecessary medication costs. From a clinical perspective, it is often observed that some patients with severe psoriasis benefit from a TNF inhibitor and others from drugs targeting the IL23/Th17 axis. The effect of certain drugs can decline with time, possibly reflecting a shift in the underlying immune profile or immunogenicity. The majority of papers investigating cytokine levels in psoriasis focus on patients as a group with comparison to healthy controls. Only a few reports investigate treatment effects on cytokine levels 17 and the intra-individual variability over time. This paper is, however, focused on cytokine levels in individuals over time, in the light of disease activity and treatment effect. The expanding knowledge regarding immune-mediated diseases makes the search for new biomarkers highly relevant.
A recent meta-analysis concluded that levels of TNF-α, IFN-γ, IL-2, IL-6, IL-8, IL-18, IL-22 were higher in psoriasis patients than in healthy controls, but this was not the case for IL-1β, IL-4, IL-10, IL-12, IL-17, IL-21, IL-23. 18 Regarding disease severity, PASI has been found to be correlated with IL-6, IL-8, IL-12, IL-17, IL-18, TNF-α and IFN-γ in some studies, but not in others. 12, [19] [20] [21] [22] [23] [24] [25] [26] [27] Differences in sample collection, storage and assessment methodologies may influence in part explain conflicting results.
It is well established that IL-17A is a key cytokine in psoriasis pathogenesis.
2 Pharmaceuticals targeting the IL-23/ Th17 axis are highly effective. 28 Congruently, we found that an increase of serum IL-17A by 1 pg/mL was associated with four times increased risk of severe psoriasis, PASI > 10. Furthermore, the pro-inflammatory cytokines IL-1β, IL-6, IL-12, IL-23, TNF and IFN-α induce, at different steps, the differentiation of Th1 and Th17 cells. 3 Our linear regression analyses indicated that the levels of TNF, IFN-γ and IL-2, and IL-17A could be predicted from the level of these mentioned cytokines upstream in the pathogenesis. The interaction between T cells and IL-2 is important for both tolerance and immunity. We found that improvement of PASI positively correlated with a fold change of IL-2. This is supported by a recent study which found that IL-2 was negatively correlated with active psoriasis. 17 Our data also revealed a correlation between IL-2 and IL-17A at inclusion, which reflect that both the Th1 and Th17 pathways are activated. One role of IL-2 in psoriasis may be differentiation of immature T cells into regulatory T cells. Further, IL-2 also facilitate the differentiation of antigen exposed T cells into effector and memory cells. In our cohort, levels of IL-2 correlated with improvement of quality of life. However, the role of IL-2 in depression is currently debated. 29, 30 IL-12 and IL-23 are instrumental in the differentiation of naïve T cells into Th1 and Th17 cells, respectively, and they share a common subunit, p40 (targeted by ustekinumab). The active IL-12 is the heterodimeric p70, comprised of p40 and the unique subunit p35. Surprisingly, decrease of IL12p70 at follow-up was associated with reduced chance of achieving PASI90 and FC of IL-12p70 positively correlated with PASI improvement. The literature provides reports on both elevated (IL-12p40) 12 and reduced (subunit not specified) 24 levels of IL-12 compared to healthy controls. Different methodologies and detection of distinct subunits of IL-12 might explain these discrepancies. Noteworthy, the Th2 associated IL-5 correlated positively with a good clinical response, possibly reflecting restitution of the Th1/Th2 balance. A decrease in the immune regulatory cytokine IL-22 was associated with lower chance of achieving PASI90. IL-22 has been shown to correlate with psoriasis, but can have diverse biological activity resulting in protective or pathogenic effects. 31 Further, reduction of GM-CSF during treatment was also associated with poor clinical response. GM-CSF has the ability to inhibit neutrophil migration and induce anti-apoptotic signalling pathways, both of which might be of importance in psoriasis. These functions can be influenced by IL-17.
32
The anti-inflammatory cytokine IL-10 executes important regulatory functions and can be involved in autoimmune diseases. 33 In psoriasis, genetic variants and reduced levels of IL-10 have been reported. 24, 34 To this end, our data show that increased levels of IL-10 at follow-SOLBERG ET AL.
up was associated with good treatment response (PASI90). Even though low-dose IL-10 administration can be beneficial in psoriasis, clinical use has been halted because of adverse events. 35 Psoriasis is associated with adiposity, and the patients in our study had high BMI. 36 Adipose tissue is one source of TNF, and we found a correlation between BMI and TNF, in congruence with reports in obese individuals. 37 Moreover, TNF inhibition is associated with weight gain, while drugs targeting the IL-23/Th17 axis are not. 38 In addition, high BMI has been associated with poor treatment response. 39 Further, we found that IL-22 and IL-1RA correlated with BMI. It was recently discovered that IL-22 is associated with obesity and type 2 diabetes. 40 Variants in the gene encoding IL-1RA have also been linked to adiposity. 41 The clinical effect of all four biological drugs in this study, measured by PASI and DLQI, was excellent. Since the levels of cytokines detected were low, changes at follow-up were difficult to uncover. We were not able to show decrease of TNF in patients receiving anti-TNF treatment or reduction of IL-12 or IL-17 in patients receiving ustekinumab or secukinumab, respectively.
Limitations of the study are low patient numbers for subgroup analyses and detection mode of cytokines by the assay. Serum measurements might not be the most sensitive way to monitor levels of cytokines that exert their effect mostly in local tissue. Some of the patients were already on methotrexate at inclusion or were prescribed the drug after starting on infliximab, but concomitant use did not seem to have a major impact on their cytokine levels. Healthy age-matched controls were not included in this study, as the aim was to evaluate intra-individual changes of cytokine levels in the light of disease severity and biological treatment.
Treatment of inflammatory diseases has improved tremendously over the last two decades. Still, clinicians often struggle to optimize individualized therapy of psoriasis vulgaris. There is currently no laboratory test to evaluate severity of or treatment effect in psoriasis, but inflammation markers (CRP, SR), trough levels and antidrug antibodies are used to some extent. 42 Our results indicate that increase of serum IL-2 is associated with both improvement of disease severity and quality of life and confirm that the serum level of IL-17A is associated with disease severity. In addition, the data unveiled that increases in IL-5, IL-10, IL-12, IL-22 and GM-CSF levels correlated with clinical response to treatment. Future studies using more sensitive methodologies, including patient groups where treatment choice is based on individual immune profile, might shed light on the usefulness of serum cytokines as biomarkers in treatment algorithms aiming at optimizing therapeutic strategies in psoriasis patients.
